Advances in the Management of Oligometastatic Disease in Non-colorectal Non-neuroendocrine Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 314
Special Issue Editor
Special Issue Information
Dear Colleagues,
Most metastatic solid tumors present with multiple and multiorgan spread and are associated with high mortality rates despite medical evolution. The oligometastatic disease concept was first described in 1995 by Hellman and Weichselbaum. It is defined as low volume metastatic disease with a limited number and size of metastatic lesions (up to five and not necessarily in the same organ). It is postulated that it may be a tumor with a different biology and, therefore, with improved prognosis.
Surgery has become an evidence-based potential curative treatment for patients with colorectal and neuroendocrine liver metastases, associated with significantly improved survival. Therefore, it has entered clinical practice and is now the standard treatment.
By contrast, surgical treatment for non-colorectal, non-neuroendocrine oligometastatic disease has always been considered marginal and remains poorly investigated. Traditionally, it has been treated with systemic therapy, and more recently with local ablative treatment, too. Nevertheless, surgery has been suggested as an available form of treatment in a subset of patients, supported by recent evidence from various high-volume centers.
In oligometastatic disease management, surgery with radical intent should be investigated more to highlight its role in terms of overall survival, relapse of cancer, and quality of life.
Dr. Stefania Brozzetti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oligometastatic disease
- surgery
- non-colorectal, non-neuroendocrine tumors
- metastatic solid tumors
- neuroendocrine liver metastases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
